Table 4 Associations of combined biomarkers with clinical and pathologic characteristics in 226 consecutive patients treated with radical cystectomy for urothelial cell carcinoma of the bladder
p53 and pRB expression | p53 and p21 expression | p53 and p27 expression | |||||||
|---|---|---|---|---|---|---|---|---|---|
One altered | Both altered | P | One altered | Both altered | P | One altered | Both altered | P | |
Total (%) | 88 (39) | 72 (32) | 108 (48) | 44 (20) | 92 (41) | 82 (36) | |||
Gender (%) | |||||||||
Female | 19 (41) | 16 (35) | 24 (52) | 8 (17) | 19 (41) | 20 (43) | |||
Male | 69 (38) | 56 (31) | 0.673 | 84 (47) | 36 (20) | 0.797 | 73 (41) | 62 (34) | 0.308 |
Pathologic tumor stage (%) | |||||||||
pTa, pTis, or pT1 | 17 (40) | 6 (14) | 14 (33) | 6 (14) | 17 (41) | 8 (19) | |||
pT2 | 25 (38) | 14 (22) | 30 (46) | 7 (11) | 27 (42) | 16 (25) | |||
pT3 | 32 (39) | 35 (42) | 45 (54) | 19 (23) | 34 (41) | 40 (48) | |||
pT4 | 14 (39) | 17 (47) | <0.001 | 19 (53) | 12 (33) | <0.001 | 14 (39) | 18 (50) | <0.001 |
Pathological grade (%) | |||||||||
Grade 1 or 2 | 9 (53) | 0 | 7 (41) | 0 | 8 (47) | 1 (6) | |||
Grade 3 | 79 (38) | 72 (34) | 0.012 | 101 (48) | 44 (21) | 0.023 | 84 (40) | 81 (39) | 0.009 |
Lymph node status (%)a | |||||||||
N0 | 61 (38) | 39 (24) | 72 (45) | 23 (14) | 68 (43) | 42 (26) | |||
N1, N2 | 27 (42) | 32 (49) | <0.001 | 35 (54) | 21 (32) | <0.001 | 24 (37) | 39 (60) | <0.001 |
Lymphovascular invasion (%)a | |||||||||
Negative | 47 (38) | 27 (22) | 53 (43) | 17 (14) | 50 (40) | 32 (26) | |||
Positive | 41 (41) | 44 (44) | <0.001 | 54 (53) | 27 (27) | <0.001 | 42 (42) | 49 (49) | <0.001 |
Concomitant CIS (%)a | |||||||||
Negative | 48 (36) | 39 (30) | 66 (50) | 20 (15) | 48 (36) | 44 (33) | |||
Positive | 40 (43) | 32 (34) | 0.175 | 41 (44) | 24 (26) | 0.139 | 44 (47) | 37 (40) | 0.009 |
Stage grouping a | |||||||||
Organ confined | 36 (37) | 16 (17) | 39 (40) | 9 (9) | 39 (40) | 19 (20) | |||
Extra-vesical extension | 25 (39) | 24 (38) | 34 (53) | 14 (22) | 29 (45) | 24 (38) | |||
Lymph node metastases | 27 (42) | 32 (49) | <0.001 | 35 (54) | 21 (32) | <0.001 | 24 (37) | 39 (60) | <0.001 |
pRB and p21 expression | pRB and p27 expression | p21 and p27 expression | |||||||
|---|---|---|---|---|---|---|---|---|---|
Total (%) | 102 (45) | 43 (19) | 88 (39) | 80 (35) | 112 (50) | 50 (22) | |||
Gender (%) | |||||||||
Female | 29 (63) | 6 (13) | 18 (39) | 21 (46) | 27 (59) | 11 (24) | |||
Male | 73 (41) | 37 (21) | 0.054 | 70 (39) | 59 (33) | 0.124 | 85 (47) | 39 (22) | 0.174 |
Pathologic tumor stage (%) | |||||||||
pTa, pTis, or pT1 | 15 (36) | 6 (14) | 14 (33) | 10 (24) | 13 (31) | 9 (21) | |||
pT2 | 25 (39) | 9 (14) | 22 (34) | 18 (28) | 33 (51) | 8 (12) | |||
pT3 | 43 (52) | 17 (21) | 38 (46) | 35 (42) | 47 (57) | 21 (25) | |||
pT4 | 19 (53) | 11 (31) | 0.010 | 14 (39) | 17 (47) | <0.001 | 19 (53) | 12 (33) | <0.001 |
Pathological grade (%) | |||||||||
Grade 1 or 2 | 6 (35) | 3 (18) | 7 (41) | 4 (24) | 7 (41) | 3 (18) | |||
Grade 3 | 96 (46) | 40 (19) | 0.589 | 81 (39) | 76 (36) | 0.492 | 105 (50) | 47 (23) | 0.472 |
Lymph node status (%)a | |||||||||
N0 | 65 (41) | 29 (18) | 59 (37) | 49 (31) | 76 (48) | 30 (19) | |||
N1, N2 | 36 (55) | 14 (22) | 0.034 | 29 (45) | 30 (46) | 0.001 | 35 (54) | 20 (31) | 0.012 |
Lymphovascular invasion (%)a | |||||||||
Negative | 48 (38) | 21 (17) | 39 (32) | 39 (32) | 51 (41) | 26 (21) | |||
Positive | 53 (53) | 22 (22) | 0.015 | 49 (49) | 40 (40) | <0.001 | 60 (59) | 24 (24) | 0.002 |
Concomitant CIS (%)a | |||||||||
Negative | 54 (41) | 28 (21) | 42 (32) | 49 (37) | 64 (49) | 28 (21) | |||
Positive | 47 (51) | 15 (16) | 0.337 | 46 (50) | 30 (32) | 0.017 | 47 (51) | 22 (24) | 0.748 |
Stage grouping a | |||||||||
Organ-confined | 35 (36) | 13 (13) | 31 (32) | 25 (26) | 42 (43) | 14 (14) | |||
Extra-vesical extension | 31 (48) | 16 (25) | 28 (44) | 25 (39) | 35 (55) | 16 (25) | |||
Lymph node metastases | 36 (55) | 14 (22) | 0.002 | 29 (45) | 30 (46) | 0.001 | 35 (54) | 20 (31) | 0.001 |
